Ariad Pharmaceuticals Inc fka ARIA

[iandy]

"Bafetinib (INNO-406) does not sufficiently cross intact or disrupted blood-brain barrier, and therefore, systemic administration of bafetinib is not recommended when investigating this drug as a treatment for brain tumours."

INNO-406 was the drug of choice in the PLOS One PD study Peter cited.

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0065129

Our studies reveal that INNO-406 is capable of preventing the progression of dopaminergic neuronal damage in a toxin-induced C57 mouse model of PD.

Bafetinib also has more affinity for Bcr-Abl than nilotinib (but less than dasatinib) but only targets Bcr-Abl and Src family kinases Lck and Lyn; with unrivalled specificity which suggests the probability of fewer adverse effects.